[1] HU Z, LI M, CHEN Z, et al. Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018. Transl Lung Cancer Res. 2019;8(6):1091-1106.
[2] DIMAKAKOS E, LIVANIOS K, GKIOZOS I, et al. New data for venous thromboembolism in patients with small cell lung cancer: A review. Phlebology. 2018;33(8):517-522.
[3] 鄢俊,钟志宏,施华球.miRNA-520a-3p调控MAP3K2表达对肺癌干细胞凋亡的影响[J].中国组织工程研究,2018,22(13):2051-2056.
[4] 项保利,钱海红,张志林,等.肺癌组织中干细胞转录因子Sox2和Oct4表达与微血管密度的相关性[J].中国组织工程研究,2017, 21(13):2114-2119.
[5] 彭兰清,郑巧,姚德蛟.肿瘤微环境与肺癌术后患者预后的关系[J].医学综述,2020,6(13):2570-2574,2579.
[6] FENOUILLE N, BASSIL CF, BEN-SAHRA I, et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017;23(3):301-313.
[7] LANG WJ, CHEN FY. The reciprocal link between EVI1 and miRNAs in human malignancies. Gene. 2018;672:56-63.
[8] 陈曦,李依敏,万福生.miRNA-206与肿瘤发生发展的研究进展[J].南昌大学学报(医学版),2017,57(1):97-101.
[9] 杨旸,王一喆,郑春雷,等.抑制AKT通路对埃克替尼耐药的非小细胞肺癌细胞迁移能力的影响[J].中国医科大学学报,2019,48(6): 502-506.
[10] 黄婉兰,陈宏鹏,林春平.吉非替尼靶向治疗EGFR阳性晚期非小细胞肺癌的疗效及对患者EGFR、Her-2、P-Akt和ERCC1的影响[J].海南医学,2020,31(11):1373-1376.
[11] 陈全,刘佳霖,贺静荣,等.磁性纳米粒介导沉默PI3Kγ基因调控肿瘤相关巨噬细胞抗小鼠肺癌细胞效应的研究[J].中国细胞生物学学报,2020,42(2):296-311.
[12] 董超,罗春香,杨润祥.PI3K/AKT通路及其抑制剂在肺癌治疗中的研究进展[J].中国临床医生杂志,2017,45(10):13-16.
[13] 彭卓,党晓燕,张秋红,等.肺癌细胞株A549的常见肿瘤干细胞抗原分析和细胞分选比较[J].中国组织工程研究,2017,21(25):3989-3994.
[14] 余仁春,胡圆,孙春明,等.Evi1基因对胶质瘤细胞株U87/U251增殖、侵袭的影响[J].临床神经外科杂志,2017,14(6):417-422.
[15] HOU CG, LUO XY, LI G. Diagnostic and Prognostic Value of Serum MicroRNA-206 in Patients with Gastric Cancer. Cell Physiol Biochem. 2016;39(4):1512-1520.
[16] 薛俊杰,李婧瑜,张莉,等.缝隙连接蛋白43在骨关节炎软骨及细胞中表达及shRNA慢病毒载体的构建[J].中国组织工程研究,2020, 24(23):3627-3635.
[17] 王宁,陈俊毅,朱伦井,等.慢病毒介导沉默P75神经营养因子受体联合神经生长因子过表达促进大鼠骨髓间充质干细胞的增殖[J].中国组织工程研究,2020,24(25):3988-3993.
[18] 方盛华,王碧荣,邓旭斌.EVI1基因对鼻咽癌细胞增殖及侵袭能力的影响[J].广东医学,2018,39(12):1780-1785.
[19] ZHAO L, XUE M, ZHANG L, et al. MicroRNA-4268 inhibits cell proliferation via AKT/JNK signalling pathways by targeting Rab6B in human gastric cancer. Cancer Gene Ther. 2020;27(6):461-472.
[20] 周菁,郭丽.DLL3沉默抑制小细胞肺癌细胞系H592的增殖和迁移[J].江苏大学学报(医学版),2020,30(4):330-335.
[21] 孙彦珍,李珍,袁征.小檗碱对肺癌干细胞增殖和凋亡的影响及其机制[J].中国组织工程研究,2017,21(9):1313-1318.
[22] 郎雯竞,朱坚轶,陈芳源.逆转录病毒结合位点-1蛋白在血液系统肿瘤中的研究进展[J].国际输血及血液学杂志,2017,40(6):539-543.
[23] ROCKFIELD S, KEE Y, NANJUNDAN M. Chronic iron exposure and c-Myc/H-ras-mediated transformation in fallopian tube cells alter the expression of EVI1, amplified at 3q26.2 in ovarian cancer. Oncogenesis. 2019;8(9):46.
[24] HELLER G, ROMMER A, STEINLEITNER K, et al. EVI1 promotes tumor growth via transcriptional repression of MS4A3. J Hematol Oncol. 2015;8:28.
[25] 赵宝祥,李华,张亚君,等.血清癌胚抗原、神经元特异性烯醇化酶、microRNA-20a和microRNA-210联合检测对早期小细胞肺癌的诊断价值[J].新乡医学院学报,2019,36(5):452-454.
[26] 郑文,贺莉芳.微小RNA在非小细胞肺癌细胞生长、凋亡及糖代谢过程中作用机制的研究进展[J].山东医药,2019,59(21):93-95.
[27] 刘大海,罗杰,马虎.miRNA与非小细胞肺癌放射敏感相关性研究进展[J].中华肿瘤防治杂志,2020,27(1):75-79.
[28] 耿帅,郭宏举,史宁,等.微RNA对肿瘤调控机制的研究进展[J].中国新药与临床杂志,2020,39(4):193-197.
[29] 于森,孟祥宁,傅松滨.表观遗传修饰与肿瘤细胞基因组不稳定性的关系[J].国际遗传学杂志,2020,43(1):13-20.
[30] 张百红,岳红云.表观遗传修饰剂在实体肿瘤中的研究进展[J].兰州大学学报(医学版),2019,45(5):14-19.
[31] 王文静,王晓霏,刘利英,等.miR-338-3p在恶性肿瘤中的表达异常及其表观遗传组蛋白的修饰位点[J].西安交通大学学报(医学版), 2019,40(5):706-710,721.
[32] FRICK E, GUDJONSSON T, EYFJORD J, et al. CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer. Oncotarget. 2019;10(45):4664-4678.
[33] 赵丽蓉,李小霞,姜蓬垒,等.c-myb基因启动子表观遗传修饰对该基因表达的影响[J].基因组学与应用生物学,2019,38(9):3973-3980.
[34] 晏强,周献青,薛雯,等.表观遗传DNA甲基化和组蛋白修饰与疾病关系的研究进展[J].医学综述,2017,23(16):3160-3163,3169.
[35] DU G, ZHOU J, CHENG L, et al. High Expression of miR-206 Predicts Adverse Outcomes: A Potential Therapeutic Target for Esophageal Cancer. Comb Chem High Throughput Screen. 2019;22(9):599-611.
[36] ZHANG X, ZENG Y, QU Q, et al. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017; 22(6):1026-1033.
[37] LIU X, SUN L, ZHANG S, et al. GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling. J Cell Physiol. 2020;235(11):7747-7756.
[38] LI H, ZHANG Q, WU Q, et al. Interleukin-22 secreted by cancer-associated fibroblasts regulates the proliferation and metastasis of lung cancer cells via the PI3K-Akt-mTOR signaling pathway. Am J Transl Res. 2019;11(7):4077-4088.
[39] WANG H, YU Z, HUO S, et al. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer. Int J Biochem Cell Biol. 2018;94:98-106.
[40] YANG X, GAO J, GUO J, et al. Anti-lung cancer activity and inhibitory mechanisms of a novel Calothrixin A derivative. Life Sci. 2019;219:20-30. |